Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-1931

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 71335-1931). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Biso Api Structure (Api Pic New1)

FDA Label Image

Hctz Api Structure (Api Pic New2)

FDA Label Image

Label (Lbl713351931)

Label (Lbl713351931)
This is a description of a medication called Bisoprolol Fumarate/Hctz in round and yellow tablets with the dosage of 2.5/6.25mg. The drug is produced by Edenbridge Pharmaceuticals LLC and comes in a bottle of 100 tablets. The text includes important information such as the drug's strength, manufacturer, dosage, storage temperatures, and an NDC number for drug identification.*
FDA Label Image

Table 1 (Table 1 New)

Table 1 (Table 1 New)
This appears to be a table showing the results of two studies related to the effects of drugs on blood pressure (systolic/diastolic) and heart rate. However, without further context or a clear indication of what the drugs being studied are, it is difficult to provide a more specific description or analysis.*
FDA Label Image

Table-3 (Table 3 New)

Table-3 (Table 3 New)
This is a chart presenting the % of patients who experienced adverse effects during a drug trial. The chart breaks down the adverse effects based on body system and provides the % of patients that had adverse experiences in the placebo group and the drug group. Some of the adverse effects listed include chest pain, coughing, dizziness, headache, diarrhea, nausea, and loss of libido.*
FDA Label Image

Table-2 (Table New 2)

Table-2 (Table New 2)
The text provides data on serum potassium levels in a study conducted in the US. It appears to be a placebo-controlled study and includes numerical data on the mean change in potassium levels in milliequivalents per liter (mEq/L) over a specific period. The text also shows the percentage of participants with hypokalemia. However, without additional context, it is not possible to determine the purpose or findings of the study.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.